ArticleHaematologica2023
Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes.
Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Rare dual-clone phenomenon: concurrent λ AL amyloidosis and κ restricted B-cell lymphoproliferative disorders.Haematologica · 2026Article
- Waldenstrom Macroglobulinemia Leading to Cholestatic Liver Injury and Rapid Progression to Liver Failure.ACG case reports journal · 2026Article
- Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.Research square · 2026Article
- Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.American journal of cardiovascular disease · 2026Article
- Extent of bone marrow infiltration predicts disease progression in asymptomatic Waldenström macroglobulinemia.Discover oncology · 2025Article
- Cardiac light chain amyloidosis secondary to Waldenström's macroglobulinemia: A case report and review.Experimental and therapeutic medicine · 2025Article
- Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.Reviews in cardiovascular medicine · 2025Review
- Monoclonal Gammopathy-Associated Neuropathy.Current hematologic malignancy reports · 2024Review
- Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function.Blood advances · 2024Article
- Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Waldenström Macroglobulinemia-Induced Cardiac Amyloid Light Chain Amyloidosis.Ochsner journal · 2024Article
- A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Frontiers in medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.